SLBT · Why this verdict
Why SL Science Holding (SLBT) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score4.3/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
SL Science shows weak fundamental quality: no competitive moat and a weak 0/9 Piotroski F-Score. Quality breakdown | The Piotroski F-Score should rise above 4/9 and moat characteristics should improve over the next several quarters. | →Stable |
| CounterA weak Piotroski score on an early-stage biotech is common pre-commercialization and may not be predictive of the pipeline's ultimate value. | ||
Technically, the setup is a falling knife: a death cross, price below all moving averages, RSI at 39, and bearish MACD, with the moving average sloping down -4.3% over 30 days in a confirmed downtrend. Momentum breakdown | Price should reclaim the 200-day moving average and RSI should recover above 50 over the next quarter to break the downtrend. | →Stable |
| CounterOn-balance volume is rising even as price falls, suggesting some accumulation is occurring beneath the surface of the confirmed downtrend, which can sometimes precede a reversal. | ||
Modeled upside differs sharply depending on methodology: the resistance-based price target implies 137% upside, while the engine's own asymmetry check separately models just 0.0% upside. Targets | The two upside estimates should converge, with the asymmetry-adjusted upside moving toward the resistance-implied level as technical clarity improves, or the resistance target should be revised down to match the more conservative asymmetry read. | →Stable |
| CounterA 137% resistance-implied target on a stock in a confirmed downtrend with no competitive moat is more likely the artifact of a stale or distant resistance level than genuine achievable upside, meaning the conservative 0% asymmetry read is probably closer to reality. | ||
The key risk list separately flags negative price momentum and a position below the long-term trend as standalone risk factors. Key risks | The stock should reclaim its long-term trend (200-day moving average) and momentum should turn positive over the next two quarters for these flagged risks to clear. | →Stable |
| CounterThese flagged risks largely restate the same underlying downtrend already captured in the momentum data, so their resolution is not independent of that broader technical picture. | ||
SL Science shows weak fundamental quality: no competitive moat and a weak 0/9 Piotroski F-Score.
→StableQuality breakdown
- Expectation
- The Piotroski F-Score should rise above 4/9 and moat characteristics should improve over the next several quarters.
CounterA weak Piotroski score on an early-stage biotech is common pre-commercialization and may not be predictive of the pipeline's ultimate value.
Technically, the setup is a falling knife: a death cross, price below all moving averages, RSI at 39, and bearish MACD, with the moving average sloping down -4.3% over 30 days in a confirmed downtrend.
→StableMomentum breakdown
- Expectation
- Price should reclaim the 200-day moving average and RSI should recover above 50 over the next quarter to break the downtrend.
CounterOn-balance volume is rising even as price falls, suggesting some accumulation is occurring beneath the surface of the confirmed downtrend, which can sometimes precede a reversal.
Modeled upside differs sharply depending on methodology: the resistance-based price target implies 137% upside, while the engine's own asymmetry check separately models just 0.0% upside.
→StableTargets
- Expectation
- The two upside estimates should converge, with the asymmetry-adjusted upside moving toward the resistance-implied level as technical clarity improves, or the resistance target should be revised down to match the more conservative asymmetry read.
CounterA 137% resistance-implied target on a stock in a confirmed downtrend with no competitive moat is more likely the artifact of a stale or distant resistance level than genuine achievable upside, meaning the conservative 0% asymmetry read is probably closer to reality.
The key risk list separately flags negative price momentum and a position below the long-term trend as standalone risk factors.
→StableKey risks
- Expectation
- The stock should reclaim its long-term trend (200-day moving average) and momentum should turn positive over the next two quarters for these flagged risks to clear.
CounterThese flagged risks largely restate the same underlying downtrend already captured in the momentum data, so their resolution is not independent of that broader technical picture.
TrendMatrix Research · core thesis
Engine thesis — one sentence
SL Science Holding shows weak fundamental quality (0/9 Piotroski, no moat) and a confirmed falling-knife downtrend (death cross, RSI 39, bearish MACD), and the engine's own asymmetry check models 0% upside even though a resistance-based price target implies 137% upside — a conflict the data does not resolve, keeping the stock flagged for exit.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
0.9/10data confidence 71%| Component | Sub-score |
|---|---|
| Gross margin | 0.0 |
| Op margin | 0.0 |
| Net margin | 0.0 |
| Moat | 4.5 |
| Piotroski F | 0.0 |
- ▸No competitive moat
- ▸Weak Piotroski F-Score: 0/9
- ▸Quality concerns
Growth
5.0/10data confidence 50%Momentum
3.9/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 4.5 |
| MACD | 3.9 |
| OBV | 10.0 |
| MA position | 1.0 |
| Volume | 0.0 |
- ▸Volume accumulation (rising OBV)
- ▸Below 200-MA, MA slope -4.5%/30d — confirmed downtrend
Sentiment
4.6/10data confidence 67%| Component | Sub-score |
|---|---|
| LLM sentiment | 4.2 |
| Analyst rating | 5.0 |
Insider
5.0/10data confidence 50%Peer rank
5.0/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 5.0 |
| quality rank | 5.0 |
| growth rank | 5.0 |
Technical
5.2/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 6.4 |
| support resistance | 8.5 |
| 52w position | 0.0 |
| gap | 6.0 |
Risk (lower is worse)
2.5/10data confidence 40%| Component | Sub-score |
|---|---|
| volatility | 0.0 |
| news risk | 5.0 |
Catalyst
8.0/10data confidence 25%| Component | Sub-score |
|---|---|
| news activity | 8.0 |
How the verdict was assembled
Engine trigger
Quality below minimum threshold.
Engine technical detail
verdict_path:
L1:HARD_BLOCKPassed (6)
- INSIDER:OK
- 8K:CLEAN
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:NO_DATE
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (2)
- MOMENTUM:3.9<4.5
- DEATH_CROSS:HARD_BLOCK
Warning (1)
- ASYMMETRY:UPSIDE_EXHAUSTED (upside=0.0%)
Reward-to-Risk
0.00
Upside
+0.0%
Downside
15.0%
Sizing output
AVOID
SetupRange Bound — RSI 47 mid-range, Bollinger mid-band
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Drawdown -68% (>40% off 52w high), Binary industry: Biotechnology
Investment implication
The L1 gate blocked the positive-verdict path: a hard-floor threshold was breached, so dimensional pillars — including Catalyst at 8.0 could not lift the engine output above the verdict floor. Failed gate signal: MOMENTUM:3.9<4.5.
The strongest dimensions are Catalyst at 8.0, Technical at 5.2, and Value at 5.0; the weakest are Quality at 0.9, Risk (lower is worse) at 2.5, and Momentum at 3.9. The V9 engine flagged 2 failed gates with 1 warning, producing an asymmetric reward-to-risk of 0.00 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Weak Quality No Moat
Trip ifThe Piotroski F-Score rises above 4 from the current 0/9, or the moat score rises above 6.0 from the current 4.5.
- P2Confirmed Falling Knife Downtrend
Trip ifPrice fails to reclaim the 200-day moving average within 6 months, or RSI stays below 30 for more than 4 consecutive weeks.
- P3Upside Estimate Conflict
Trip ifThe asymmetry-adjusted modeled upside rises above 20% from the current 0.0%, narrowing the gap with the 137% resistance-implied target.
- P4Flagged Momentum And Trend Risk
Trip ifMomentum score falls below 3.0 from the current 3.6, or the stock trades more than 20% further below its long-term trend.